Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free HEMO Stock Alerts

Hemogenyx Pharmaceuticals (HEMO) Competitors

Hemogenyx Pharmaceuticals logo
GBX 444.50 -8.50 (-1.88%)
As of 09/15/2026 12:29 PM Eastern
Compare

HEMO vs. TILS, VSN, SCLP, MPH, and 4BB

Should you buy Hemogenyx Pharmaceuticals stock or one of its competitors? Hemogenyx Pharmaceuticals's main competitors and comparable companies include Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), and 4basebio (4BB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

Tiziana Life Sciences has higher earnings, but lower revenue than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

In the previous week, Tiziana Life Sciences' average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Tiziana Life Sciences Neutral
Hemogenyx Pharmaceuticals Neutral

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Hemogenyx Pharmaceuticals beats Tiziana Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Verseon?

Verseon (LON:VSN) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VerseonN/AN/AN/A-£14.30N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Verseon's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
VerseonN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Verseon's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Verseon Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Verseon and Hemogenyx Pharmaceuticals tied by winning 3 of the 6 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Scancell?

Hemogenyx Pharmaceuticals (LON:HEMO) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Hemogenyx Pharmaceuticals has a beta of 1.487, indicating that its share price is 49% more volatile than the broader market. Comparatively, Scancell has a beta of 0.687, indicating that its share price is 31% less volatile than the broader market.

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Comparatively, 13.2% of Scancell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Scancell had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Hemogenyx Pharmaceuticals. Scancell's average media sentiment score of 0.67 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that Scancell is being referred to more favorably in the news media.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Scancell Positive

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Scancell -116.98%90.29%-45.28%

Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than Scancell. Scancell is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Scancell£4.71M22.42-£6.75M-£0.55N/A

Summary

Scancell beats Hemogenyx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Hemogenyx Pharmaceuticals Neutral

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

Summary

Mereo BioPharma Group plc (MPH.L) beats Hemogenyx Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to 4basebio?

4basebio (LON:4BB) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

4basebio's return on equity of -231.29% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -231.29% -54.30%
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

4basebio currently has a consensus price target of GBX 1,400, suggesting a potential upside of 174.51%. Given 4basebio's stronger consensus rating and higher probable upside, equities analysts clearly believe 4basebio is more favorable than Hemogenyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Hemogenyx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.487, indicating that its stock price is 49% more volatile than the broader market.

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£1.69M46.65-£9.84M-£109.00N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

In the previous week, 4basebio's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
4basebio Neutral
Hemogenyx Pharmaceuticals Neutral

0.9% of 4basebio shares are held by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

4basebio beats Hemogenyx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get Hemogenyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HEMO vs. The Competition

Export
MetricHemogenyx PharmaceuticalsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£30.14M£3.89B£7.21B£2.88B
Dividend YieldN/A3.65%2.57%6.26%
P/E Ratio-2.6114.11272.84366.92
Price / SalesN/A1,434.33701.6990,001.88
Price / Cash2.05108.9477.7127.89
Price / Book1,804.2815.1710.376.33
Net Income-£6.89K-£22.78M£3.49B£5.89B
7 Day Performance-9.29%-0.71%-0.76%-0.36%
1 Month Performance-25.50%0.29%-0.39%-0.68%
1 Year Performance-63.97%39.41%18.93%19.86%

Hemogenyx Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 444.50
-1.9%		N/A-66.7%£30.14MN/AN/A14
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
SCLP
Scancell
N/AGBX 10.06
+1.1%		N/A+6.3%£107.44M£4.71MN/A51
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HEMO) was last updated on 9/16/2026 by MarketBeat.com Staff.
From Our Partners
This Microcap Is Taking On the Energy Industry’s Dirtiest Problems
A small company has developed water-based cleaning technologies aimed at some of heavy industry's toughest pro...
Wall Street Logic | Sponsoredtc pixel
“This is the Perfect Tech Stock”
Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...
Brownstone Research | Sponsoredtc pixel
Jon Najarian's #1 Energy Trade for 2026
Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...
Banyan Hill Publishing | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The national debt just passed $39 trillion
The U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...
US Gold Bureau | Sponsoredtc pixel
You’ve never seen anything like this before
For centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...
Porter & Company | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel